Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization

Abstract

The new McDonald diagnostic criteria for multiple sclerosis (MS) incorporate detailed criteria for the interpretation and classification of magnetic resonance imaging (MRI) findings, but, in contrast, provide no instructions for the interpretation of clinical findings. Because MS according to the McDonald criteria is one of the primary endpoints in a large trial enrolling patients after the first manifestation suggestive for a demyelinating disease (BENEFIT study), it was decided to organize a centralized eligibility assessment for this trial. During this eligibility assessment it was observed that there were marked inconsistencies in the decisions of participating neurologists with respect to the classification of clinical symptoms as being caused by one or more lesions provoking discussions in about one in every five patients. This paper describes these inconsistencies and their sources, and recommends a systematic approach that attempts to reduce the variability in interpreting clinical findings.

Keywords

diagnosis symptoms and signs

Get full access to this article

View all access options for this article.

References

McDonald WI , Compston A , Edan G , Goodkin D , Hartung HP , Lublin FB et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis . Ann Neurol 2001; 50: 121-127 .

Polman CH , Freedman M , Hartung H , Kappos L , Miller D , Montalban X et al. Interferon beta-1b (Betaferon®/Betaseron®) in early treatment of multiple sclerosis: the BENEFIT study . Mult Scler 2003; 9: S93-S93 .

Comi G , Filippi M , Barkhof F , Durelli L , Edan G , Fernandez O et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study . Lancet 2001; 357: 1576-1582 .

Jacobs LD , Beck RW , Simon JH , Kinkel RP , Brownscheidle CM , Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group . N Engl J Med 2000; 343: 898-904 .

Zipoli V , Portaccio E , Siracusa G , Pracucci G , Sorbi S , Amato MP. Interobserver agreement on Poser’s and the new McDonald’s diagnostic criteria for multiple sclerosis . Mult Scler 2003; 9: 481-485 .